Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone

Carlos K.H. Wong\textsuperscript{1,2,3} PhD, Kristy T.K. Lau\textsuperscript{1} MSc, Ivan C.H. Au\textsuperscript{1} BSc, Xi Xiong\textsuperscript{1} MSc, Matthew S. H. Chung\textsuperscript{1} BSc, Eric H. Y. Lau\textsuperscript{3,4} PhD, Benjamin J. Cowling\textsuperscript{3,4} PhD

\textsuperscript{1} Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

\textsuperscript{2} Department of Family Medicine and Primary Care, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

\textsuperscript{3} Laboratory of Data Discovery for Health Limited, Hong Kong Science Park, New Territories, Hong Kong SAR, China

\textsuperscript{4} WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

**Corresponding author:**

Carlos KH Wong, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Rm 1-01, 1/F, Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road, Pokfulam, Hong Kong. Tel: (+852) 2831-5055 Fax: (+852) 2814-7475. Email: carlosho@hku.hk

**Summary:** Initiation of remdesivir prior to or simultaneously with dexamethasone was associated with significantly shorter time to clinical improvement and positive IgG antibody, lower risk of death, in addition to a shorter length of hospital stay in patients with moderate COVID-19.
Abstract

**Background:** Evidence is lacking about any additional benefits of introducing remdesivir on top of dexamethasone, and the optimal timing of initiation.

**Methods:** In a territory-wide cohort of 10,445 COVID-19 patients from Hong Kong who were hospitalized between 21st January 2020 and 31st January 2021, 1,544 patients had received dexamethasone during hospitalization. Exposure group consisted of patients who had initiated remdesivir prior to dexamethasone (n=93), or co-initiated the two drugs simultaneously (n=373); whereas non-exposure group included patients who were given remdesivir after dexamethasone (n=149), or those without remdesivir use (n=929). Multiple imputation and inverse probability of treatment weighting for propensity score were applied and hazard ratios (HR) of event outcomes were estimated using Cox regression models.

**Results:** Time to clinical improvement (HR=1.23, 95%CI 1.02-1.49, p=0.032) and positive IgG antibody (HR=1.22, 95%CI 1.02-1.46, p=0.029) were significantly shorter in the exposure group than that of non-exposure. The exposure group had a shorter hospital length of stay by 2.65 days among survivors, lower WHO clinical progression scale scores from five days of follow-up onwards, lower risks of in-hospital death (HR=0.59, 95%CI 0.36-0.98, p=0.042) and composite outcomes; and without experiencing an increased risk of ARDS. Differences in the cumulative direct medical costs between groups were no longer significant from 17 days of follow-up onwards.

**Conclusions:** Initiation of remdesivir prior to or simultaneously with dexamethasone was associated with significantly shorter time to clinical improvement and positive IgG antibody, lower risk of in-hospital death, in addition to shorter length of hospital stay in patients with moderate COVID-19.

**Keywords:** COVID-19, remdesivir, dexamethasone, time to clinical improvement, length of hospital stay
Introduction

In respond to the Coronavirus Disease 2019 (COVID-19) pandemic, a number of pharmaceutical agents have been repurposed for managing hospitalized patients with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection,[1, 2] where remdesivir and dexamethasone are two potential drugs under consideration.[3, 4] International guidelines generally recommend remdesivir for hospitalized COVID-19 patients requiring supplemental oxygen but not mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and dexamethasone among those requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO.[5-8]

For patients requiring supplemental oxygen but not invasive mechanical ventilation or ECMO, some guidelines suggest the combination of remdesivir and dexamethasone as a therapeutic option; yet combining an antiviral with an anti-inflammatory corticosteroid has been proposed from the theoretical perspective, where its safety and efficacy remain to be determined.[5, 7] To our knowledge, only one cohort study has specifically examined the effects of remdesivir and dexamethasone combination on COVID-19 patients so far, concluding that this drug combination on top of standard care was associated with significantly lower 30-day mortality and the need for mechanical ventilation compared to standard care alone.[9] However, this before-and-after study poses some inherent limitations that may have influenced the interpretation of findings, such as possible differences in standard care between the two time periods, and a substantially higher proportion of patients receiving supplemental oxygen in the intervention group at baseline.[9]

Accordingly, clinical evidence on the combined use of remdesivir and dexamethasone is urgently needed, namely longer-term clinical outcomes stratified by patient subgroups, viral clearance, and the optimal dose, timing and duration of respective therapy.[1, 8, 10-15] Therefore, this observational cohort study aims to conduct a propensity score (PS) analysis of hospitalized COVID-19 patients who had initiated remdesivir prior to or simultaneously with dexamethasone versus those who had initiated remdesivir after that of dexamethasone or who were not given remdesivir at all. With respect to the timing of remdesivir administration, it is hypothesized that clinical benefits would be observed with early or co-initiation of the antiviral relative to dexamethasone, compared to delayed introduction or non-users.
Methods

Data source and study population

A territory-wide retrospective cohort of all COVID-19 patients who were consecutively admitted with positive reverse transcription polymerase chain reaction (RT-PCR) results to public hospitals in the Hong Kong Special Administrative Region, China was reviewed for the period from 21st January 2020 to 31st January 2021. Electronic medical records of COVID-19 patients were retrieved from the Hospital Authority. Our cohort comprised cases of mild disease to critically ill, which was fully representative of the hospitalized COVID-19 patient population in the local region. Data cutoff date was 30th April 2021.

Both remdesivir and dexamethasone were treatment options for hospitalized COVID-19 patients in Hong Kong since July 2020.[16] Oral or intravenous dexamethasone of 6mg once daily for up to 10 days was recommended for hospitalized patients with pneumonia, and those who required supplemental oxygen or invasive mechanical ventilation.[16] A 5-day regimen of intravenous remdesivir of 200mg on the first day and 100mg once daily on subsequent days was recommended for hospitalized patients with pneumonia, who were breathing ambient air or requiring supplemental oxygen; and a 10-day regimen for those on invasive mechanical ventilation or ECMO.[16]

‘New-user’ design [17] was applied to include hospitalized COVID-19 patients who had initiated oral or intravenous dexamethasone during admission, in an effort to mitigate the selection and immortal time biases. Patients who were discharged alive or those deceased on or before the initial dispensing day of dexamethasone were excluded. The baseline date was defined as that of dexamethasone initiation.

Treatment exposure and follow-up period

Patients who had initiated remdesivir intravenously prior to dexamethasone, or co-initiated remdesivir and dexamethasone on the same day during hospitalization were categorized as the exposure (or denoted as remdesivir-dexamethasone) group. Patients who had received their first dose of remdesivir after dexamethasone initiation, or who were not administered with remdesivir at all were classified as the non-exposure (or denoted as dexamethasone) group. The distribution of timing of dexamethasone initiation following hospital admission is
shown in Supplementary Figure 1. Patients were followed up until in-hospital death, hospital discharge, or the data cutoff date, whichever came first.

**Baseline covariates**

Baseline covariates of patients included details on dexamethasone and remdesivir use, age, sex, time period of hospitalization, pre-existing comorbidities, use of long-term medications (within three years before baseline), admission via emergency department, in-hospital pharmacological and non-pharmacological treatments, laboratory parameters (taken from the closest measurement before baseline during hospitalization), and clinical severity determined by the WHO clinical progression scale (CPS) (Table 1).[18] Acute respiratory distress syndrome (ARDS) diagnosed on or before baseline was also identified.

**Outcomes**

The primary outcome was time to clinical improvement, defined as a reduction on the WHO CPS [18] by at least one score. Secondary outcomes were time to hospital discharge; recovery without the need for oxygen therapy; viral clearance (first negative PCR results); low viral load (Ct value ≥35 cycles); positive antibody against COVID-19 (first positive IgG antibody); ARDS; composite outcome of in-hospital death or invasive mechanical ventilation; composite outcome of in-hospital death, invasive mechanical ventilation, or intensive care unit (ICU) admission; and in-hospital death.

Other study outcomes included hospital length of stay (LOS) for discharged survivors; mean changes in laboratory parameters from baseline to the last available measurement during hospitalization; mean changes in the WHO CPS score, clinical status as indicated by the WHO CPS, and cumulative direct medical costs incurred from baseline to 90-day follow-up. Components of the direct medical costs are listed in Supplementary Table 1, where the reference costs were obtained from a public website [19] and the Hospital Authority.[20]

**Statistical analyses**

A PS model with treatment group as the outcome variable conditional on the aforementioned baseline covariates in a logistic regression model was constructed, and the propensity of receiving remdesivir prior to dexamethasone versus not receiving remdesivir was estimated.
Inverse probability of treatment weighting (IPTW) using the PS was performed. Weight truncation at the 1st and 99th percentile of the observed PS weighting distribution was applied to address extreme weights.[21] Multiple imputation by chained equation was implemented to impute missing laboratory parameters (Supplementary Table 2) included in the PS model using the observed baseline covariates without any missing information. Rubin’s rules were applied to pool the treatment effects estimated from the 20 independent imputed datasets.[22] Balance of each baseline covariate before and after PS weighting was assessed using standardized mean difference (SMD), with SMD >0.2 indicating covariate imbalance.[23]

Cox regression models weighted by the IPTW were fitted to estimate the treatment effects on primary and secondary outcomes, expressed in terms of hazard ratio (HR) and 95% confidence interval (CI). Linear regression models using the IPTW were applied to estimate the treatments effects on other outcomes in continuous form.

Several sensitivity analyses were performed, namely to extend the follow-up beyond hospital discharge; limit the observation period to at most 90 days; and adopt the complete-case approach using IPTW. Besides, subgroup analyses were performed with the re-calculation of PS and IPTW within each of the following subgroups: age; sex; timing of dexamethasone initiation; exclusion of non-remdesivir users or patients who had initiated remdesivir after that of dexamethasone; with or without concomitant use of other systemic steroids (including hydrocortisone, prednisolone, or methylprednisolone); oral or intravenous administration of dexamethasone; dosage of dexamethasone; early or co-initiation of remdesivir relative to dexamethasone; with or without the need for invasive mechanical ventilation or ECMO, and ICU admission.

All statistical analyses were performed using STATA Version 16 (StataCorp LP, College Station, TX). All significance tests were two-tailed, where p<0.05 was considered statistically significant.

**Results**

Among 10,445 patients admitted to hospital with COVID-19 between 21st January 2020 and 31st January 2021, 1,544 patients were administered dexamethasone orally or intravenously during hospitalization (Supplementary Figure 2). In this cohort, 615 (39.8%) patients had
ever received remdesivir, of whom 93 (15.1%) were given remdesivir prior to dexamethasone initiation, 373 (60.7%) had co-initiated remdesivir and dexamethasone on the same day, and 149 (24.2%) were given remdesivir after dexamethasone initiation (Supplementary Table 3). The median of delay of remdesivir initiation following dexamethasone was 2 (interquartile range: 1-4) days. Exposure group consisted of 466 patients with remdesivir use prior to or co-initiated with dexamethasone; whereas the non-exposure group included 1,078 patients who had initiated remdesivir after dexamethasone, or those who were never treated with remdesivir. The median follow-up period of patients in exposure and non-exposure groups were 13 (interquartile range: 8-24) and 13 (9-23) days, respectively (Supplementary Table 4).

Baseline characteristics of patients in the exposure and non-exposure groups before and after PS weighting are listed in Table 1. After multiple imputation and weighting, PS distribution between the two groups highly overlapped (Supplementary Figure 3). Clinical severity of COVID-19, pre-existing comorbidities, long-term medication use, treatments received during hospitalization, and laboratory parameters were comparable between groups. Overall, baseline characteristics were well balanced with all SMDs <0.2.

Time to clinical improvement (median 12 vs 13 days; HR=1.23, 95%CI 1.02-1.49, p=0.032) and positive IgG antibody (median 5 vs 6 days; HR=1.22, 95%CI 1.02-1.46, p=0.029) were significantly shorter in the exposure group than that of non-exposure (Table 2 and Figure 1). Although the time to hospital discharge and recovery were not significantly shorter for the exposure group, survivors had a shorter hospital LOS by 2.65 days (95%CI 1.01-4.29, p=0.002) than their non-exposure counterparts. Trends towards faster viral clearance and low viral load were demonstrated in the exposure group compared to non-exposure. Furthermore, exposure group was associated with significantly lower risks of in-hospital death (HR=0.59, 95%CI 0.36-0.98, p=0.042) and composite outcomes (in-hospital death or invasive mechanical ventilation: HR=0.67, 95%CI 0.46-0.96, p=0.031; in-hospital death, invasive mechanical ventilation or ICU admission: HR=0.64, 95%CI 0.43-0.97, p=0.034) than the non-exposure group. Meanwhile, no significant differences in the risk of ARDS were identified between the two groups.

Results of various sensitivity and subgroup analyses showed similar trends and were generally comparable to those of main analysis (Supplementary Tables 5 and 6). In addition to significantly shorter time to clinical improvement and hospital discharge, faster recovery
could be observed in the subgroup of patients initiating remdesivir prior to that of
dexamethasone (excluding patients with co-initiation of the two drugs) compared to late
introduction or no remdesivir use at all; and achieving positive IgG antibody faster, with
significantly lower risks of composite outcomes and ARDS among those initiating remdesivir
prior to or simultaneously with that of dexamethasone compared to late introduction
(initiating remdesivir after dexamethasone).

As illustrated in Figure 2 and Supplementary Table 7, the proportion of patients with in-
hospital death or on mechanical ventilation on 90-day was significantly lower in the exposure
group (7% vs 13%, p<0.001), and lower WHO CPS scores were observed among patients of
the exposure group compared to their non-exposure counterparts from five days of follow-up
onwards. Mean WHO CPS scores in the exposure group were significantly lower on 30-day
(1.27 vs 1.90, p<0.001), 60-day (0.88 vs 1.49, p<0.001), and 90-day (0.79 vs 1.38, p<0.001).
Mean cumulative direct medical costs incurred by patients of the two groups from baseline to
90-day follow-up revealed that the differences converged to non-significance from 17 days
onwards.

Changes in laboratory parameters from baseline to the last available measurement were
estimated within each group and by differences between groups (Supplementary Table 8 and
Supplementary Figure 4). A significantly larger increase in mean platelet count (135.3 vs
120.4 x10^9/L, p<0.001) was observed in the exposure group compared to that of non-
exposure. Notably, both baseline and last measurements of the two groups were within
the normal range. In contrast, patients in the exposure group had significantly smaller increases
in mean alkaline phosphatase (ALP) (5.3 vs 8.8 U/L, p=0.048) and alanine transaminase
(ALT) (12.5 vs 35.7 U/L, p=0.002), yet a significantly smaller decrease in mean hemoglobin
(-0.6 vs -0.9 g/dL, p<0.001) than their non-exposure counterparts.

**Discussion**

Among patients with mainly moderate COVID-19 who were treated with dexamethasone
during hospitalization, initiating remdesivir prior to or simultaneously with the corticosteroid
was associated with significantly shorter time to clinical improvement and positive IgG
antibody, lower risks of in-hospital death and composite outcomes, and a shorter LOS.
Trends towards faster hospital discharge and viral clearance were also evident in the exposure group compared to non-exposure, without imposing any significant risk of ARDS.

In a retrospective cohort study with the majority of COVID-19 patients requiring low-flow oxygen therapy at baseline, no significant reduction of mortality was found with the combination of dexamethasone and remdesivir compared to remdesivir treatment alone, where a longer time to clinical improvement (hospital discharge or reduction in the WHO severity score by at least two points) was even observed with the combined use of remdesivir with corticosteroids; however, the authors noted that patients on the drug combination might have been more severely ill.[24] Meanwhile, our study design was unique in considering the timing of remdesivir initiation, revealing that remdesivir might confer additional benefits in promoting clinical improvement among dexamethasone users when it was initiated prior to or simultaneously with dexamethasone compared to late introduction or no remdesivir use, in a patient population with mainly moderate COVID-19 that would have benefited from this antiviral.[25-27]

In line with previous findings, early use of remdesivir was associated with a shorter hospital LOS, and it could potentially facilitate recovery and hospital discharge of COVID-19 patients.[3, 28-31] While remdesivir has not been consistently shown to reduce the risk of mortality compared to placebo or standard care, such discrepancy could be dependent on the severity of COVID-19 and level of respiratory support required.[24-26, 28, 30, 32] Consistent with the before-and-after study suggesting reduced mortality and the need for mechanical ventilation with remdesivir and dexamethasone combination versus standard care alone,[9] our results have further demonstrated that early or co-initiation of remdesivir with dexamethasone was associated with lower risks of these negative outcomes compared to late introduction or not using the antiviral at all. Overall, our study has provided preliminary evidence to support the notion that combining dexamethasone with remdesivir would be more beneficial to using the corticosteroid alone, in addition to the preferred timing of antiviral initiation relative to anti-inflammatory agents,[1] as evidenced by the potential clinical benefits and the absence of any significant harms in this patient population with mainly moderate COVID-19.

In response to whether the timing or sequence of drug initiation would have an impact on patient outcomes, our subgroup analyses further demonstrated that initiating remdesivir prior
to dexamethasone was associated with better clinical outcomes than late introduction of remdesivir after the corticosteroid or not using the antiviral at all; and results might even be more prominent when remdesivir was administered prior to or simultaneously with dexamethasone compared to late introduction of the antiviral. These observations were justifiable based on the theoretical understanding of the progression of a viral infection, where early introduction of antivirals might help to inhibit viral replication and possibly prevent the ‘cytokine storm’, followed by the addition of anti-inflammatory agents (such as corticosteroids) to suppress the hyper-inflammation should it develop.[1, 11, 14, 33]

Meanwhile, as corticosteroids are immunosuppressive, they could potentially delay viral clearance by hampering the host antiviral immune response, especially when they are administered early with uncontrolled viral replication, given at high doses, or to patients with non-severe COVID-19.[13, 14, 33-37] Based on our results, initiation of remdesivir prior to or simultaneously with dexamethasone was associated with a trend towards faster viral clearance, compared to initiating the antiviral after dexamethasone or not using remdesivir at all; in addition to a significantly shorter time to positive IgG antibody, which has been associated with faster viral clearance in itself [38]. Therefore, our study supported the idea of introducing remdesivir prior to dexamethasone in low doses [1] for moderate COVID-19.

In terms of changes in laboratory parameters, the exposure group had significantly smaller increases in ALP and ALT, and a smaller decrease in hemoglobin compared to non-exposure group. These observations were in favor of patients with early or co-initiation of remdesivir with dexamethasone, as elevated liver enzymes, and the presence of anemia, have been observed to associate with severe COVID-19 or even an increased risk of mortality.[39-41]

Utilizing electronic medical records available from the public healthcare service provider, this retrospective cohort study offered a real-life picture of the clinical management of hospitalized COVID-19 patients. In addition to reporting various clinical outcomes and changes in virologic measures, our study had compared the results over 90 days of follow-up. Our findings have also provided insights into the preferred timing of remdesivir initiation relative to dexamethasone. Nevertheless, several limitations of this study should be acknowledged. Firstly, owing its observational nature, unmeasured or residual confounding is possible, despite our attempt to balance the baseline covariates with multiple imputation and weighting. While observational studies using PS weighting cannot substitute randomized
controlled trials, we have accounted for all possible pretreatment variables in PS estimation in order to adjust for confounding by indication.[42] Secondly, as the majority of our cohort did not require supplemental oxygen or mechanical ventilation, and were treated with interferon therapy at baseline, our results would not be generalizable to other patient populations or subgroups. Thirdly, our findings might not apply to other antivirals or corticosteroids, as their safety and efficacy could differ by drug type, dosage, and duration of therapy. Lastly, effects of the remdesivir and dexamethasone combination with other concomitant drugs for COVID-19 were not explored, such as tocilizumab and baricitinib, as their use was very limited in our cohort. Results of the ACTT-4 trial are pending, which will compare the outcomes of baricitinib plus remdesivir versus dexamethasone plus remdesivir in hospitalized COVID-19 patients.[43]

Among hospitalized patients with mainly moderate COVID-19 who were treated with dexamethasone, initiating remdesivir prior to or simultaneously with the corticosteroid was potentially associated with shorter time to clinical improvement and achieving positive IgG antibody, lower risks of in-hospital death and composite outcomes, in addition to a shorter LOS, compared to late introduction of remdesivir after dexamethasone or not using the antiviral at all. This study provided preliminary evidence to support early or co-initiation of remdesivir with dexamethasone, and emphasized the need for further research on this drug combination with other potential therapeutics targeting immune dysregulation.[7, 10, 11]
NOTES

Contributors: C.K.H.W. reviewed the literature, designed statistical analysis, conducted analyses, wrote the manuscript; K.T.K.L. reviewed the literature, contributed to the interpretation of the analysis, and wrote the manuscript. C.H.A. and M.C. conducted analyses. X.X. and E.H.Y.L. contributed to the interpretation of the analysis. B.J.C. contributed to the interpretation of the analysis, critically reviewed and revised the manuscript. All authors contributed to the interpretation of the analysis, critically reviewed and revised the manuscript, and approved the final manuscript as submitted. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Acknowledgements: We thank the Hong Kong Hospital Authority for the data provision. The data that support the findings of this study were provided by the Hong Kong Hospital Authority. Restrictions apply to the availability of these data, which were used under license for this study. The study protocol was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster (Reference No. UW 20-493). Given the extraordinary nature of the COVID-19 pandemic, individual patient informed consent was not required for this retrospective cohort study using anonymised data.

Funding
We received financial support from the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region, China (grant no. COVID190210). The funders did not have any role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of Interest: B.J.C consults for Roche, Sanofi Pasteur, GSK, AstraZeneca, and Moderna and is supported by the AIR@innoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government; payments made to their institution from HMRF, RGC, NIH, CDC, NIAID, ITC, Wellcome, WHO outside of the study. CKHW and EHYL reports payments made to their institution from General Research Fund, Research Grant Council, Government of the Hong Kong Special Administrative Region, China; EuroQol Group Research Foundation outside the duration of the study. The authors report no other potential conflicts of interest.
References

1. Abdelrahman Z, Liu Q, Jiang S, et al. Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. Frontiers in Pharmacology 2021; 12(30): 607408.

2. Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370: m2980.

3. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine 2020; 383(19): 1813-26.

4. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 2021; 384(8): 693-704.

5. Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal 2021; 57(4): 2100048.

6. Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed 2021/06/19.

7. National Institutes of Health. Therapeutic Management of Adults With COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/management/therapeutic-management/. Accessed 2021/06/19.

8. World Health Organization. Therapeutics and COVID-19: living guideline. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1. Accessed 2021/06/19.

9. Benfield T, Bodilsen J, Brieghel C, et al. Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clinical Infectious Diseases 2021.

10. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs 2020; 80(18): 1929-46.

11. Feuillet V, Canard B, Trautmann A. Combining Antivirals and Immunomodulators to Fight COVID-19. Trends in Immunology 2021; 42(1): 31-44.

12. Lee TC, McDonald EG, Butler-Laporte G, Harrison LB, Cheng MP, Brophy JM. Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. International Journal of Infectious Diseases 2021; 104: 671-6.

13. Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. The Lancet Respiratory Medicine 2020; 8(12): 1170-2.

14. Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. The Journal of Clinical Investigation 2020; 130(12): 6218-21.

15. Waterer GW, Rello J. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. Infectious Diseases and Therapy 2020; 9(4): 701-5.

16. Department of Pharmacy QMH, Hospital Authority. Interim Drug Treatment Handbook for COVID-19, 9th Version. 9th version ed, 2021.

17. Lund JL, Richardson DB, Stürmer T. The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. Current Epidemiology Reports 2015; 2(4): 221-8.

18. Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious Diseases 2020; 20(8): e192-e7.
19. Gilead Sciences I. An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences. Available at: https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman-ceo-gilead-sciences. Accessed 28/05/2021.
20. Hospital Authority. Hospital Authority Ordinance (Chapter 113) - Revision to list of charges, 2017.
21. Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 2019; 367: i5657.
22. Leyrat C, Seaman SR, White IR, et al. Propensity score analysis with partially observed covariates: How should multiple imputation be used? Statistical Methods in Medical Research 2017; 28(1): 3-19.
23. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine 2009; 28(25): 3083-107.
24. Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA Network Open 2021; 4(3): e213071.
25. Davis MR, McCreary EK, Pogue JM. That Escalated Quickly: Remdesivir’s Place in Therapy for COVID-19. Infectious Diseases and Therapy 2020; 9(3): 525-36.
26. Kaka AS, MacDonald R, Greer N, et al. Major Update: Remdesivir for Adults With COVID-19. Annals of Internal Medicine 2021; 174(5): 663-72.
27. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020; 324(11): 1048-57.
28. Olender SA, Perez KK, Go AS, et al. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clinical Infectious Diseases 2020.
29. Paranjape N, Husain M, Priestley J, Koonjah Y, Watts C, Havlik J. Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study. Infectious Diseases in Clinical Practice 2020; Publish Ahead of Print.
30. Reddy Vegivinti CT, Pederson JM, Saravu K, et al. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Annals of Medicine and Surgery 2021; 62: 43-8.
31. Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. Clinical Infectious Diseases 2021.
32. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384(6): 497-511.
33. Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nature Reviews Immunology 2020; 20(10): 587-8.
34. Chen Y, Li L. Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19. Clinical Infectious Diseases 2021; 72(7): 1298-300.
35. Li S, Hu Z, Song X. High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19. Clinical Infectious Diseases 2021; 72(7): 1297-8.
36. Shuto H, Komiya K, Yamasue M, et al. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Scientific Reports 2020; 10(1): 20935.
37. Zhan Y, Shang J, Gu Y, Huang Q, Xie J. Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis. Journal of Medical Virology 2021; 93(7): 4292-302.
38. Masiá M, Telenti G, Fernández M, et al. SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response. Open Forum Infectious Diseases 2021; 8(2): ofab005.
39. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. Journal of Hepatology 2020; 73(3): 566-74.
40. Faghih Dinevari M, Somi MH, Sadeghi Majd E, Abbasalizad Farhangi M, Niknáz Z. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a prospective study in Iran. BMC Infectious Diseases 2021; 21(1): 170.
41. Medetalibeyoglu A, Catma Y, Senkal N, et al. The effect of liver test abnormalities on the prognosis of COVID-19. Annals of Hepatology 2020; 19(6): 614-21.
42. Bergstra SA, Sepriano A, Ramiro S, Landewé R. Three handy tips and a practical guide to improve your propensity score models. RMD Open 2019; 5(1): e000953.
43. ClinicalTrials.gov. Adaptive COVID-19 Treatment Trial 4 (ACTT-4). Available at: https://clinicaltrials.gov/ct2/show/NCT04640168. Accessed 2021/06/19.
Figure Legends

Figure 1. Kaplan-Meier survival curves for at least 1-point clinical improvement on WHO clinical progression scale, hospital discharge, recovery, low viral load, IgG antibody, and in-hospital death

Shown are Kaplan-Meier survival curves for at least 1-point clinical improvement on the WHO clinical progression scale, hospital discharge, recovery, low viral load, IgG antibody, and in-hospital death. Shaded areas indicate 95% confidence intervals. Estimates of the hazard ratio and 95% confidence intervals were derived from Cox regression models weighted by the IPTW.

Figure 2. Comparisons of (a) clinical status measured by WHO Clinical Progression Scale score, (b) WHO Clinical Progression Scale score, and (c) cumulative direct medical costs by days from baseline to 90-day among patients between remdesivir-dexamethasone and dexamethasone group

Figure 2a shows the changes from baseline in clinical status (in-hospital death, levels of respiratory support, and hospital discharge) on 7, 15, 30, 60, and 90 days of follow-up for the remdesivir-dexamethasone and dexamethasone groups. Figures 2b and 2c show the mean WHO clinical progression scale scores and mean cumulative direct medical costs incurred from baseline to 90-day follow-up by treatment groups.
Table 1. Baseline characteristics of patients hospitalized with COVID-19 in the two treatment groups before and after multiple imputation and propensity score weighting

| Baseline characteristics | Remdesivir-Dexamethasone (n=466) | Dexamethasone (n=1,078) | Remdesivir-Dexamethasone (n=466) | Dexamethasone (n=1,078) |
|-------------------------|----------------------------------|-------------------------|----------------------------------|-------------------------|
|                         | N / Mean % / SD                  | N / Mean % / SD         | N / Mean % / SD                  | N / Mean % / SD         |
| **Age, years †**        |                                  |                         |                                  |                         |
| ≤65                     | 64.8 (12.5%)                     | 64.3 (14.4%)            | 64.0 (11.8%)                     | 64.5 (14.4%)            |
| >65                     |                                  |                         |                                  |                         |
| **Sex**                 |                                  |                         |                                  |                         |
| Male                    | 264 (56.7%)                      | 628 (58.3%)             |                                  |                         |
| Female                  | 202 (43.3%)                      | 450 (41.7%)             |                                  |                         |
| **Period**              |                                  |                         |                                  |                         |
| 21st January 2020 - 30th November 2020 | 64 (13.7%) | 717 (66.5%) | 4.7 (2.0%) | 4.9 (2.2%) |
| 1st December 2020 - 31st January 2021 | 402 (86.3%) | 361 (33.5%) | 4.8 (2.0%) | 4.8 (2.2%) |
| **Pre-existing comorbidities** |                                  |                         |                                  |                         |
| Charlson Comorbidity Index †‡ |                                  |                         |                                  |                         |
| 1-4                     | 237 (50.9%)                      | 523 (48.6%)             | 4.7 (2.0%)                      | 4.9 (2.2%)             |
| 5-6                     | 156 (33.5%)                      | 332 (30.8%)             | 0.13 (51.0%)                    | 0.13 (50.1%)           |
| 7-14                    | 73 (15.7%)                       | 222 (20.6%)             | 0.01 (30.0%)                    | 0.02 (31.3%)           |
| Diabetes mellitus       | 295 (63.3%)                      | 615 (57.1%)             | 0.09 (38.3%)                    | 0.09 (37.2%)           |
| Hypertension            | 295 (63.3%)                      | 615 (57.1%)             | 0.13 (61.3%)                    | 0.13 (55.8%)           |
| Liver disease           | 156 (33.5%)                      | 332 (30.8%)             | 0.01 (12.4%)                    | 0.01 (11.1%)           |
| Chronic lung disease    | 73 (15.7%)                       | 222 (20.6%)             | 0.02 (9.5%)                     | 0.02 (10.9%)           |
| Chronic heart disease   | 194 (41.6%)                      | 401 (37.2%)             | 0.16 (12.8%)                    | 0.16 (16.5%)           |
| Chronic kidney disease  | 46 (9.9%)                        | 209 (19.4%)             | 0.27 (13.5%)                    | 0.27 (18.7%)           |
| Malignancy              | 11 (2.4%)                        | 32 (3.0%)               | 0.04 (6.7%)                     | 0.04 (2.9%)            |
| **Long-term medications** |                                  |                         |                                  |                         |
| ACEI/ARB                | 143 (30.7%)                      | 284 (26.3%)             | 0.10 (28.2%)                    | 0.10 (24.8%)           |
| Anticoagulant           | 256 (54.9%)                      | 471 (43.7%)             | 0.23 (55.0%)                    | 0.23 (48.9%)           |
| Antiplatelet            | 78 (16.7%)                       | 200 (18.6%)             | 0.05 (13.5%)                    | 0.05 (16.8%)           |
| Lipid-lowering agent    | 171 (36.7%)                      | 351 (32.6%)             | 0.09 (39.0%)                    | 0.09 (31.0%)           |
| NSAID                   | 89 (19.1%)                       | 244 (22.6%)             | 0.09 (15.4%)                    | 0.09 (21.2%)           |
| **Time from admission to remdesivir initiation, days ‡** | 3.6 (3.2%) | 6.0 (3.7%) | 0.73 (4.1) | 3.3 (5.5) | 3.6 (5.4) | 0.0
|                                            | 595.9 | 235.7 | 604.7 | 219.1 | 0.04 | 599.1 | 228.0 | 608.4 | 210.1 | 0.04 |
|-------------------------------------------|-------|-------|-------|-------|------|-------|-------|-------|-------|------|
| Cumulative dosage of remdesivir, mg †     |        |       |       |       |      |       |       |       |       |      |
| Duration of use of remdesivir, days †     | 4.3   | 2.1   | 4.5   | 1.9   | 0.12 | 4.3   | 2.0   | 4.4   | 1.9   | 0.12 |
| Time from admission to dexamethasone initiation, days † | 4.1 | 3.5 | 4.5 | 4.1 | 0.11 | 4.7 | 3.4 | 4.3 | 3.9 | 0.11 |
| Administration route of dexamethasone     |       |       |       |       |      |       |       |       |       |      |
| Oral                                      | 64    | (13.7%) | 283  | (26.3%) | 0.32 | (19.3%) | 273.3% | 0.1   |       | 9    |
| Intravenous injection                     | 402   | (86.3%) | 795  | (73.7%) | 0.32 | (80.7%) | 72.7% | 0.1   |       | 0    |
| Dosage of dexamethasone                   |       |       |       |       |      |       |       |       |       |      |
| Up to 6mg daily                           | 185   | (39.7%) | 518  | (48.1%) | 0.17 | (46.4%) | 46.9% | 0.0   |       | 1    |
| More than 6mg daily                       | 281   | (60.3%) | 560  | (51.9%) | 0.17 | (53.6%) | 53.1% | 0.0   |       | 1    |
| Cumulative dosage of dexamethasone, mg †  | 51.5  | 68.5  | 53.0  | 51.8  | 0.03 | 52.8  | 79.6  | 55.2  | 55.1  | 0.04 |
| Duration of use of dexamethasone, days †  | 7.3   | 10.1  | 8.3   | 8.2   | 0.11 | 7.7   | 11.7  | 8.3   | 8.0   | 0.07 |
| Drug initiation sequence                  |       |       |       |       |      |       |       |       |       |      |
| Remdesivir followed by dexamethasone      | 93    | (20.0%) | NA   | NA   |       | (22.0%) | NA   |       |       | 0    |
| Co-initiation of remdesivir and dexamethasone | 373   | (80.0%) | NA   | NA   |       | (78.0%) | NA   |       |       | 7    |
| Treatment performed prior to dexamethasone initiation |       |       |       |       |      |       |       |       |       |      |
| Remdesivir                                | 466   | (100.0%) | 0   | (0.0%) | NA   | (100.0%) | 0.0% | NA   |       | 0.0  |
| Interferon-β-1b                           | 255   | (54.7%) | 879  | (81.5%) | 0.60 | (68.4%) | 72.1% | 0.1   |       | 8    |
| Ribavirin                                 | 139   | (29.8%) | 443  | (41.1%) | 0.24 | (45.8%) | 38.3% | 0.1   |       | 5    |
| Tocilizumab                               | 2     | (0.4%) | 25   | (2.3%) | 0.16 | (0.8%) | (2.1%) | 0.1   |       | 0    |
| Baricitinib                               | 5     | (1.1%) | 25   | (4.2%) | 0.08 | (0.8%) | (0.8%) | 0.0   |       | 0    |
| Other systemic steroids                   | 12    | (2.6%) | 45   | (4.2%) | 0.09 | (2.2%) | (3.6%) | 0.0   |       | 8    |
| EOM                                        | 1     | (0.2%) | 2    | (0.2%) | 0.01 | (0.1%) | (0.3%) | 0.0   |       | 0    |
| Ventilation                               | 63    | (13.5%) | 129  | (12.0%) | 0.05 | (11.9%) | (11.4%) | 0.0   |       | 2    |
| Invasive mechanical ventilation           | 63    | (13.5%) | 128  | (11.9%) | 0.05 | (11.9%) | (11.3%) | 0.0   |       | 2    |
| Non-invasive mechanical ventilation       | 13    | (2.8%) | 32   | (3.0%) | 0.01 | (2.6%) | (3.0%) | 0.0   |       | 2    |
| Dialysis                                  | 4     | (0.9%) | 11   | (1.0%) | 0.02 | (0.4%) | (0.8%) | 0.0   |       | 0    |
| ICU admission                              | 112   | (24.0%) | 212  | (19.7%) | 0.11 | (22.4%) | (19.7%) | 0.0   |       | 5    |
| Admission via emergency department        | 196   | (42.1%) | 670  | (62.2%) | 0.41 | (54.1%) | (56.9%) | 0.0   |       | 6    |
| WHO Clinical Progression Scale Score (range 0-10) † | 4.7 | 1.1 | 4.6 | 1.0 | 0.09 | 4.6 | 1.1 | 4.6 | 1.0 | 0.03 |
| ARDS Laboratory parameters [normal range] |       |       |       |       |      |       |       |       |       |      |
| White blood cell, ×10^9/L [3.7-9.2 ×10^9/L] | 5.7   | 2.4   | 5.7   | 2.5   | 0.00 | 5.5   | 2.2   | 5.7   | 2.5   | 0.09 |
| Neutrophil, ×10^9/L [1.7-5.8 ×10^9/L]      | 4.3   | 2.4   | 4.2   | 2.4   | 0.04 | 3.9   | 2.1   | 4.2   | 2.4   | 0.10 |
| Lymphocyte, ×10^9/L [1.0-3.1 ×10^9/L]      | 1.0   | 0.5   | 1.0   | 0.4   | 0.08 | 1.0   | 0.5   | 1.0   | 0.4   | 0.01 |
| Test                        | Unit (Range)  | Mean | SD   | Mean | SD   | Mean | SD   | Mean | SD   | Mean | SD   | Mean | SD   | Mean | SD   | Significance |
|-----------------------------|---------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|----------------|
| Platelet                   | ×10⁹/L [145-370 ×10⁹/L] | 181.7 | 61.1 | 185.6 | 72.9 | 0.06 | 176.4 | 63.3 | 183.9 | 72.3 | 0.1 | 0.0 | 1 | 0.0 | 0.0 | 0.0 |
| Lactate dehydrogenase      | U/L [110-210 U/L] | 334.1 | 138.6 | 319.0 | 142.0 | 0.11 | 320.6 | 127.7 | 324.2 | 145.7 | 0.0 | 0.0 | 3 | 0.0 | 0.0 | 0.0 |
| Creatine kinase            | U/L [26-192 U/L] | 273.2 | 461.1 | 253.7 | 516.4 | 0.04 | 269.0 | 481.5 | 258.8 | 508.7 | 0.0 | 0.0 | 2 | 0.0 | 0.0 | 0.0 |
| Total bilirubin            | μmol/L [5-27 μmol/L] | 9.5 | 6.7 | 10.0 | 7.1 | 0.07 | 9.3 | 6.0 | 9.9 | 6.8 | 0.0 | 0.0 | 8 | 0.0 | 0.0 | 0.0 |
| C-reactive protein         | mg/L [<5 mg/L] | 63.2 | 54.2 | 58.9 | 55.5 | 0.08 | 56.8 | 48.7 | 60.1 | 57.8 | 0.0 | 0.0 | 6 | 0.0 | 0.0 | 0.0 |
| Cycle threshold value      | cycle         | 23.1 | 5.0 | 24.6 | 5.5 | 0.28 | 24.9 | 6.0 | 24.1 | 5.6 | 0.1 | 0.0 | 1 | 0.1 | 0.0 | 0.0 |
| eGFR, ml/min/1.73m² (>90 ml/min/1.73m²) | 104.6 | 59.4 | 103.1 | 64.5 | 0.02 | 104.9 | 44.8 | 106.7 | 80.3 | 0.0 | 0.0 | 3 | 0.0 | 0.0 | 0.0 |
| ALP, U/L [30-120 U/L]      |               | 68.9 | 32.6 | 73.8 | 56.3 | 0.10 | 67.9 | 33.8 | 72.3 | 49.4 | 0.1 | 0.1 | 3 | 0.0 | 0.0 | 0.0 |
| ALT, U/L [<46.5 U/L]       |               | 37.3 | 25.4 | 39.1 | 40.7 | 0.05 | 36.0 | 24.4 | 38.4 | 39.2 | 0.0 | 0.0 | 7 | 0.0 | 0.0 | 0.0 |
| Hemoglobin                 | g/dL [13.4-17.1 g/dL] | 13.3 | 1.6 | 13.2 | 1.8 | 0.05 | 13.3 | 1.4 | 13.2 | 1.8 | 0.0 | 0.0 | 3 | 0.0 | 0.0 | 0.0 |

Notes:

ACEI = angiotensin converting enzyme inhibitor; ALP = alkaline phosphatase; ALT = alanine transaminase; ARB = angiotensin receptor blocker; ARDS = acute respiratory distress syndrome; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate; ICU = intensive care unit; NA = not applicable; NSAID = non-steroidal anti-inflammatory drug; SD = standard deviation; SMD = standardized mean difference

† Age, Charlson Comorbidity Index, clinical severity, cumulative dosage, duration of use of dosage, time from admission to dexamethasone initiation, and laboratory parameters on admission are presented in mean ± SD

‡ The calculation of Charlson Comorbidity Index does not include Acquired Immune Deficiency Syndrome (AIDS)

¶ SMD of <0.2 indicates covariate balance between remdesivir-dexamethasone and dexamethasone groups
Table 2. Comparison of time to clinical improvement, hospital discharge, recovery, changes in virologic measures, and risks of in-hospital death, composite outcomes, and acute respiratory distress syndrome between the two treatment groups

| Outcomes                                                                 | Before weighting | After weighting |
|--------------------------------------------------------------------------|------------------|----------------|
|                                                                          | Remdesivir-dexamethasone | Dexamethasone | Remdesivir-dexamethasone vs Dexamethasone |
|                                                                          | % (N)             | % (N)         | H R 95% CI       | P-value |
| **Clinical improvement on WHO clinical progression scale by ≥ 1 score**   | 92.1% (466)      | 88.1% (1,078) | 1.02, 1.49       | 0.03    |
| Hospital discharge                                                       | 90.6% (466)      | 87.1% (1,078) | 1.09, 1.43       | 0.09    |
| Recovery (score ≤ 4)                                                     | 79.2% (154)      | 74.5% (341)  | 0.72, 1.23       | 0.66    |
| Viral clearance (first negative PCR result)                              | 32.7% (456)      | 31.6% (1,043) | 1.09, 1.43       | 0.12    |
| Low viral load (Ct value ≥ 35)                                           | 31.3% (457)      | 31.2% (1,033) | 1.09, 1.43       | 0.17    |
| IgG antibody                                                             | 97.1% (339)      | 91.7% (806)  | 1.02, 1.46       | 0.02    |

| Outcomes                                                                 | % (N)             | % (N)         | H R 95% CI       | P-value |
|--------------------------------------------------------------------------|------------------|----------------|------------------|---------|
| **In-hospital death or invasive mechanical ventilation (score ≥ 7)**     | 14.5% (448)      | 18.8% (1,059) | 0.46, 0.96       | 0.03    |
| In-hospital death or invasive mechanical ventilation (score ≥ 7) or intensive care unit admission | 11.3% (417)      | 17.4% (1,016) | 0.43, 0.93       | 0.03    |
| In-hospital death                                                        | 7.7% (466)       | 11.6% (1,078) | 0.36, 0.98       | 0.04    |
| ARDS                                                                     | 10.7% (441)      | 8.2% (1,040)  | 0.59, 0.96       | 0.96    |

Notes:

ARDS = acute respiratory distress syndrome; CI = confidence interval; Ct = cycle threshold; HR = hazard ratio; IgG = immunoglobulin G; PCR = polymerase chain reaction

† HR >1 (or <1) indicates remdesivir-dexamethasone group was associated with better (worse) clinical improvement, early (late) hospital discharge, recovery, or achieving virologic measures compared to the dexamethasone group;

‡ HR >1 (or <1) indicates remdesivir-dexamethasone group was associated with higher (lower) risk of in-hospital death, composite outcomes, or ARDS compared to the dexamethasone group.
Figure 1

Clinical improvement on WHO clinical progression scale by ≥1 score

Hospital discharge (score ≤3)

Recovery (score ≤4)

Low viral load (Ct value ≥35)

Development of IgG antibody

In-hospital death (score = 10)

Number at risk
Remdesivir-Dexamethasone 1078 458 101 73 47 37
Dexamethasone 469 251 76 41 25 19 0

Number at risk
Remdesivir-Dexamethasone 1078 458 101 73 47 37
Dexamethasone 469 251 76 41 25 19 0

Number at risk
Remdesivir-Dexamethasone 1050 366 183 40 27 20 9
Dexamethasone 457 216 84 34 19 16 9

Number at risk
Remdesivir-Dexamethasone 896 67 5 2 2 2 9
Dexamethasone 589 29 3 2 2 2 1

Number at risk
Remdesivir-Dexamethasone 1079 574 191 112 74 49 39
Dexamethasone 498 217 99 61 34 25 13

HR=1.23
95% CI: 1.02, 1.49
P=0.032

HR=1.18
95% CI: 0.97, 1.43
P=0.095

HR=0.94
95% CI: 0.72, 1.23
P=0.663

HR=1.25
95% CI: 0.91, 1.72
P=0.177

HR=1.22
95% CI: 1.02, 1.46
P=0.029

HR=0.59
95% CI: 0.36, 0.98
P=0.042
Figure 2